Want to see ES:PRM full AI Analyst Report?
PRM Stock Chart & Stats
€13.25
-€0.04(-0.42%)
At close: 4:00 PM EST
€13.25
-€0.04(-0.42%)
Day’s Range― - ―
52-Week Range€11.30 - €13.95
Previous CloseN/A
Volume3.41K
Average Volume (3M)3.97K
Market Cap
€227.96M
Enterprise Value€225.13M
Total Cash (Recent Filing)€23.03M
Total Debt (Recent Filing)€16.28M
Price to Earnings (P/E)13.7
Beta0.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.37%
Share Statistics
EPS (TTM)0.98
Shares Outstanding17,036,577
10 Day Avg. Volume4,234
30 Day Avg. Volume3,973
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)163.15
Price to Sales (P/S)89.18
P/FCF Ratio1.24K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.16
Revenue Forecast (FY)€270.70M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetElimination of debt materially reduces financial risk and interest burden, giving durable flexibility for capital allocation, dividends or opportunistic M&A. Over the next 2–6 months this unlevered position supports resilience to shocks and strategic optionality.
Consistent Revenue GrowthSustained multi-year revenue expansion indicates stable demand across product lines and distribution channels. Combined with improved 2025 margins, it suggests durable operating leverage and product-mix gains that can underpin earnings stability beyond short-term cycles.
Improving Returns On EquityRising ROE reflects more effective use of shareholders' capital and improving profitability. This durable metric supports the company's ability to internally fund growth and sustain shareholder returns without relying on external financing, strengthening long-term fundamentals.
Bears Say
Uneven Cash GenerationVolatile operating and free cash flow, including prior negative periods and a material FCF decline in 2025 versus 2024, signals inconsistent cash conversion. This undermines capacity to fund capex, acquisitions or consistent dividends without rebuilding resilience in working-capital management.
Margin VolatilityNotable swings in gross and operating margins suggest sensitivity to input costs, pricing or mix shifts. Persistent margin volatility weakens earnings predictability and heightens execution risk for sustaining margin improvements, complicating medium-term planning and investor visibility.
Limited Capital Structure LeverageBeing unlevered reduces financial risk but constrains the company’s ability to amplify ROE through prudent debt financing. If growth opportunities require external funding, the firm may face higher equity dilution or delayed investments, limiting near-term return expansion options.
PRIM, S.A. News
PRM FAQ
What was PRIM, S.A.’s price range in the past 12 months?
PRIM, S.A. lowest stock price was €11.30 and its highest was €13.95 in the past 12 months.
What is PRIM, S.A.’s market cap?
PRIM, S.A.’s market cap is €227.96M.
When is PRIM, S.A.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PRIM, S.A.’s earnings last quarter?
Currently, no data Available
Is PRIM, S.A. overvalued?
According to Wall Street analysts PRIM, S.A.’s price is currently Overvalued.
Does PRIM, S.A. pay dividends?
PRIM, S.A. pays a Notavailable dividend of €0.105 which represents an annual dividend yield of 3.37%. See more information on PRIM, S.A. dividends here
What is PRIM, S.A.’s EPS estimate?
PRIM, S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PRIM, S.A. have?
PRIM, S.A. has 17,036,577 shares outstanding.
What happened to PRIM, S.A.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PRIM, S.A.?
Currently, no hedge funds are holding shares in ES:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PRIM, S.A.
Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassotherapy and hydrotherapy), rehabilitation, spa facilities, elderly care, and a range of supportive techniques, reaching customers within Spain and across global borders. Furthermore, the company supplies specialized goods for neuro-trauma, cardiovascular health, neuromodulation, surgical suites, endosurgical procedures, cosmetic surgery, and ear, nose, and throat (ENT) specialties. Beyond its product offerings, Prim, S.A. is involved in overseeing wellness developments, including hotel properties, vacation resorts, and athletic clubs. The firm was established in 1870 and maintains its principal office in Móstoles, Spain.
Technical Analysis
Oryzon Genomics SA
―
Pharma Mar SA
―
Atrys Health SA
―
Labiana Health SA
―
Santa Ana Global Enterprises SA
―
Options Prices
Currently, No data available
---